RNS Number : 9417J
Incanthera PLC
29 October 2024
 

 

 

 

Goal Group

                                                                                                                                                                29 October 2024

 

Incanthera plc

("Incanthera" the "Company")

Further re: Commercial Update

 

Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology, announces an update on its Skin + CELL luxury skincare range.

 

Further to the Commercial Update of 26 September 2024, the Company undertook to update the market in October regarding the timing of the European launch of Skin + CELL.  While the Company awaits clarity on timings, it remains committed to updating the market with full details as soon as these are available.

 

 

For further information please contact:

 

Incanthera plc

www.incanthera.com

 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

 

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

 

 

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600

Aquis Exchange Corporate Adviser: 

Cairn Financial Advisers LLP

Jo Turner / Liam Murray / Ed Downes

 

+44 (0) 20 7213 0880

Broker: 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney

+44 (0) 20 3650 3650/51

 

Notes to Editors

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                                               

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

About Skin + CELL

 

Skin + CELL is Incanthera's luxury skincare brand utilising our ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge pharmaceutical enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

 

Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.

Forward looking statement disclaimer

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFEUFAAELSEFS
Insetco (LSE:INC)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Insetco.
Insetco (LSE:INC)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Insetco.